Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Mar 27 04:00PM ET
14.64
Dollar change
+1.57
Percentage change
12.01
%
Index- P/E- EPS (ttm)-1.95 Insider Own10.09% Shs Outstand107.08M Perf Week7.41%
Market Cap1.57B Forward P/E- EPS next Y-1.85 Insider Trans-0.10% Shs Float96.28M Perf Month-10.18%
Income-207.04M PEG- EPS next Q-0.42 Inst Own84.70% Short Float5.76% Perf Quarter8.20%
Sales509.34M P/S3.08 EPS this Y9.68% Inst Trans2.97% Short Ratio4.46 Perf Half Y-15.13%
Book/sh3.39 P/B4.32 EPS next Y-5.30% ROA-17.71% Short Interest5.54M Perf Year-74.88%
Cash/sh8.52 P/C1.72 EPS next 5Y- ROE-51.52% 52W Range10.87 - 83.60 Perf YTD-1.94%
Dividend Est.- P/FCF- EPS past 5Y-22.97% ROI-21.60% 52W High-82.49% Beta0.41
Dividend TTM- Quick Ratio5.56 Sales past 5Y17.16% Gross Margin74.91% 52W Low34.68% ATR (14)0.94
Dividend Ex-Date- Current Ratio5.78 EPS Y/Y TTM-120.47% Oper. Margin-45.63% RSI (14)50.23 Volatility8.04% 5.89%
Employees1453 Debt/Eq1.67 Sales Y/Y TTM-5.30% Profit Margin-40.65% Recom2.14 Target Price26.43
Option/ShortYes / Yes LT Debt/Eq1.64 EPS Q/Q-23.90% Payout- Rel Volume9.59 Prev Close13.07
Sales Surprise-0.01% EPS Surprise13.69% Sales Q/Q4.17% EarningsFeb 22 BMO Avg Volume1.24M Price14.64
SMA20-2.37% SMA50-1.31% SMA200-29.81% Trades Volume11,926,038 Change12.01%
Date Action Analyst Rating Change Price Target Change
Nov-20-23Resumed JP Morgan Neutral $15
Aug-28-23Downgrade H.C. Wainwright Buy → Neutral $85 → $25
Aug-08-23Upgrade Piper Sandler Neutral → Overweight $45
Aug-04-23Initiated SVB Securities Outperform $51
Jul-31-23Upgrade Evercore ISI Underperform → In-line $33
Jun-07-23Upgrade Wedbush Underperform → Neutral $53 → $46
May-16-23Upgrade Wells Fargo Equal Weight → Overweight $70 → $104
Mar-17-23Downgrade JP Morgan Neutral → Underweight $99 → $50
Jan-06-23Downgrade Wells Fargo Overweight → Equal Weight $89 → $107
Jan-05-23Reiterated H.C. Wainwright Buy $100 → $140
Mar-27-24 04:08PM
09:29AM
09:16AM
07:14AM
07:12AM
07:05AM Loading…
07:05AM
07:00AM
Mar-13-24 09:55AM
Mar-11-24 07:00AM
Feb-23-24 11:43AM
Feb-22-24 12:15PM
08:25AM
07:36AM
07:23AM
07:00AM
07:46AM Loading…
Jan-19-24 07:46AM
Jan-18-24 02:19PM
07:00AM
Jan-11-24 09:55AM
Jan-09-24 07:00AM
Jan-08-24 07:00AM
Jan-04-24 04:05PM
Dec-27-23 07:00AM
Dec-08-23 04:09AM
Dec-04-23 04:46PM
Nov-28-23 10:51AM
07:30AM
Nov-21-23 07:00AM
Nov-14-23 09:09AM
Nov-10-23 08:00AM
06:45AM Loading…
Nov-03-23 06:45AM
Oct-30-23 02:04AM
Oct-28-23 08:39AM
Oct-26-23 04:35PM
11:00AM
08:52AM
08:30AM
07:24AM
07:00AM
Oct-15-23 06:05PM
Oct-12-23 08:00AM
Oct-02-23 07:00AM
Sep-29-23 05:00PM
Sep-18-23 11:47AM
Sep-08-23 04:01PM
Sep-06-23 02:27PM
Sep-04-23 09:30AM
Aug-31-23 06:52PM
09:55AM
Aug-29-23 06:31PM
Aug-28-23 05:15PM
04:08PM
02:19PM
12:21PM
12:16PM
12:10PM
11:47AM
09:34AM
07:27AM
07:10AM
07:00AM
Aug-25-23 08:20AM
07:00AM
Aug-15-23 09:30AM
Aug-13-23 05:49PM
Aug-09-23 10:45AM
05:10AM
Aug-08-23 04:11PM
10:02AM
Aug-04-23 09:38AM
Aug-01-23 03:54PM
Jul-27-23 06:56PM
11:30AM
08:15AM
07:07AM
07:00AM
Jul-25-23 10:01AM
Jul-21-23 08:00AM
Jul-06-23 01:17PM
Jul-03-23 08:00AM
Jun-12-23 09:30AM
05:39AM
Jun-09-23 09:45AM
Jun-07-23 11:05AM
Jun-06-23 04:02PM
04:01PM
03:40PM
02:48PM
11:50AM
10:31AM
08:31AM
08:12AM
08:05AM
08:00AM
Jun-01-23 07:01AM
May-27-23 06:14AM
May-05-23 09:54AM
05:51AM
May-04-23 01:00PM
08:35AM
NovoCure Ltd. is an oncology company which engages in the development, manufacture, and commercialization of Optune for the treatment of a variety of solid tumors. Its platform is called the Tumor Treating Field which uses electric fields tuned to specific frequencies to disrupt solid tumor cancer cell division. The company was founded by Yoram Palti in 2000 and is headquartered in St. Helier, Jersey.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
GROENHUYSEN WILHELMUS CMChief Operating OfficerMar 04 '24Sale16.011,21719,484251,235Mar 05 04:09 PM
Leonard Frank XEVP, Pres., Novocure OncologyMar 04 '24Sale16.0184013,448160,098Mar 05 04:08 PM
GROENHUYSEN WILHELMUS CMChief Operating OfficerMar 01 '24Sale16.032,10733,769252,452Mar 05 04:09 PM
Leonard Frank XEVP, Pres., Novocure OncologyMar 01 '24Sale16.031,67926,909160,938Mar 05 04:08 PM
GROENHUYSEN WILHELMUS CMChief Operating OfficerFeb 28 '24Sale16.142,30337,177254,559Feb 29 04:28 PM
Leonard Frank XEVP, Pres., Novocure OncologyFeb 28 '24Sale16.142,07833,545162,617Feb 29 04:38 PM
Shah PriteshChief Growth OfficerNov 07 '23Sale12.653824,832124,511Nov 08 04:22 PM
Cordova AshleyChief Financial OfficerNov 02 '23Option Exercise11.461752,006117,618Nov 02 04:20 PM
Cordova AshleyChief Financial OfficerOct 31 '23Option Exercise9.5817,793170,447117,443Nov 02 04:20 PM
Cordova AshleyChief Financial OfficerSep 01 '23Sale21.8288319,26599,650Sep 05 04:24 PM
GROENHUYSEN WILHELMUS CMChief Operating OfficerSep 01 '23Sale21.822946,414209,825Sep 05 04:24 PM
Shah PriteshChief Growth OfficerSep 01 '23Sale21.822735,956124,893Sep 05 04:23 PM
Cordova AshleyChief Financial OfficerAug 02 '23Sale30.251,14434,607100,533Aug 04 04:02 PM
Last Close
Mar 27 04:00PM ET
2.50
Dollar change
-0.07
Percentage change
-2.72
%
NERV Minerva Neurosciences Inc daily Stock Chart
Index- P/E- EPS (ttm)-4.65 Insider Own22.26% Shs Outstand6.99M Perf Week-7.41%
Market Cap17.48M Forward P/E- EPS next Y-4.54 Insider Trans0.00% Shs Float5.44M Perf Month-10.71%
Income-30.01M PEG- EPS next Q-1.20 Inst Own35.19% Short Float0.70% Perf Quarter-61.72%
Sales0.00M P/S- EPS this Y22.56% Inst Trans-8.22% Short Ratio0.31 Perf Half Y-65.94%
Book/sh-4.07 P/B- EPS next Y-27.17% ROA-53.59% Short Interest0.04M Perf Year52.44%
Cash/sh5.87 P/C0.43 EPS next 5Y- ROE- 52W Range1.58 - 13.49 Perf YTD-59.35%
Dividend Est.- P/FCF- EPS past 5Y14.92% ROI-56.02% 52W High-81.47% Beta0.21
Dividend TTM- Quick Ratio12.57 Sales past 5Y-20.00% Gross Margin- 52W Low58.23% ATR (14)0.45
Dividend Ex-Date- Current Ratio12.57 EPS Y/Y TTM22.60% Oper. Margin0.00% RSI (14)27.67 Volatility6.29% 7.83%
Employees9 Debt/Eq- Sales Y/Y TTM- Profit Margin- Recom3.00 Target Price11.00
Option/ShortNo / Yes LT Debt/Eq- EPS Q/Q5.37% Payout- Rel Volume0.28 Prev Close2.57
Sales Surprise- EPS Surprise-35.23% Sales Q/Q- EarningsFeb 22 BMO Avg Volume125.22K Price2.50
SMA20-6.98% SMA50-59.29% SMA200-64.32% Trades Volume34,722 Change-2.72%
Date Action Analyst Rating Change Price Target Change
Jun-08-20Reiterated H.C. Wainwright Buy $20 → $10
May-14-20Initiated BTIG Research Buy $23
Oct-02-19Reiterated Chardan Capital Markets Buy $17
Sep-25-19Initiated Chardan Capital Markets Buy $17
Sep-18-19Initiated William Blair Outperform
May-31-19Initiated H.C. Wainwright Buy
Sep-01-17Initiated Citigroup Buy $11
Mar-06-17Resumed Jefferies Buy $17
May-12-16Resumed Jefferies Buy
Feb-27-24 08:11AM
08:00AM
06:31AM
Feb-22-24 07:41AM
07:00AM
07:47AM Loading…
Nov-07-23 07:47AM
07:30AM
Oct-20-23 01:22PM
Aug-01-23 07:40AM
07:30AM
Jun-28-23 08:30AM
Jun-09-23 09:55AM
May-18-23 12:00PM
May-15-23 09:57PM
07:40AM
07:30AM Loading…
07:30AM
May-10-23 08:00AM
May-08-23 08:30AM
May-01-23 07:00AM
Mar-10-23 02:24AM
Mar-08-23 11:12PM
07:30AM
Mar-01-23 08:30AM
Dec-29-22 10:18AM
05:30AM
Dec-28-22 08:00AM
Nov-09-22 08:00AM
Nov-02-22 08:30AM
Oct-20-22 11:28AM
Oct-17-22 09:18AM
08:51AM Loading…
08:51AM
08:30AM
Sep-26-22 09:21AM
Sep-09-22 04:05PM
Aug-31-22 06:25PM
Aug-23-22 12:38PM
Aug-22-22 08:00AM
Aug-12-22 09:55AM
Aug-09-22 08:00AM
Jun-22-22 08:58AM
May-04-22 08:30AM
Apr-07-22 09:57AM
08:30AM
Mar-21-22 09:52AM
Mar-01-22 09:05AM
07:30AM
Feb-28-22 08:30AM
Dec-01-21 07:44AM
Nov-08-21 08:45AM
07:30AM
Nov-03-21 08:30AM
Nov-01-21 08:30AM
Oct-11-21 08:30AM
Oct-01-21 07:00AM
Sep-30-21 10:32AM
08:30AM
Sep-27-21 08:30AM
Sep-08-21 08:30AM
Aug-02-21 08:55AM
07:30AM
Jul-26-21 03:01PM
08:30AM
Jun-10-21 08:30AM
Jun-04-21 05:20AM
May-28-21 08:00AM
May-19-21 06:19AM
May-17-21 07:57AM
May-13-21 09:01AM
May-12-21 02:35PM
10:03AM
08:30AM
07:30AM
07:20AM
06:59AM
06:45AM
May-11-21 04:15PM
May-05-21 05:10PM
Apr-07-21 08:46AM
Apr-05-21 09:31AM
Mar-08-21 12:30PM
07:30AM
05:30AM
Mar-06-21 10:57AM
Mar-01-21 08:30AM
Feb-08-21 02:30PM
01:20PM
12:30PM
11:30AM
11:13AM
11:00AM
09:43AM
06:20AM
12:45AM
Feb-07-21 01:12PM
10:30AM
Feb-06-21 01:10PM
10:00AM
07:15AM
Feb-05-21 09:15PM
09:00PM
Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of a portfolio of product candidates to treat central nervous system diseases. It develops Roluperidone for the treatment of negative symptoms in patients with schizophrenia and MIN-301 for the treatment of Parkinson's disease. The company was founded by Rogerio Vivaldi Coelho and Goeffrey Robin Race on April 23, 2007 and is headquartered in Burlington, MA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Luthringer RemyCEOMay 02 '23Sale3.763,64113,69068,994May 02 06:15 PM
Luthringer RemyCEOMay 01 '23Sale3.8523,75391,44972,635May 02 06:15 PM
Race GeoffPresidentMay 01 '23Sale3.8522,08285,01651,324May 02 06:14 PM
Ahlholm Frederick WSVP, CFO and SecretaryMay 01 '23Sale4.483,58016,03817,518May 02 06:13 PM